AANEM

Alpine Immune Sciences Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Immunoglobulin G, ASN, PMN, UPCR, Investment, Clinical trial, American Society of Nephrology, APRIL, Glomerular filtration rate, Administration, Patient, TACI, Inflammation, Immunoglobulin A, Neonatal Fc receptor, Lupus, Infection, Research program, BAFF, SLE, ALPN, Immunoglobulin M, MD, Development, EGFR, BCMA, Society, NIH Intramural Research Program, Autoimmunity, Proteinuria, AANEM, Pharmaceutical industry, Sewage treatment, Vaccine, Paint, IgA nephropathy, AbbVie, Alpine

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results and company highlights for the third quarter ended September 30, 2023.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results and company highlights for the third quarter ended September 30, 2023.
  • “Following our data presentation, we executed a follow-on equity offering of $150 million to bolster our balance sheet.
  • Cash Position and Runway: As of September 30, 2023, Alpine’s cash and investments totaled $227.2 million compared to $273.4 million as of December 31, 2022.
  • The respective increases of $0.8 million and $2.3 million were primarily attributable to increases in personnel and legal costs.

Alpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual Meeting

Retrieved on: 
Friday, November 3, 2023
Research, Neurology, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, AANEM, Myasthenia gravis, Neonatal Fc receptor, ALPN, IgA nephropathy, Therapy, Treatment, MG, MD, Inflammation, Volunteering, Date-time group, Alpine, Immunoglobulin G, Immunoglobulin A, Immunoglobulin M, Autoimmunity, Glomerulonephritis, Pharmaceutical industry, Vaccine

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company presented new preclinical data on povetacicept in myasthenia gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting (AANEM), November 1-3, 2023 in Phoenix, Arizona.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company presented new preclinical data on povetacicept in myasthenia gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting (AANEM), November 1-3, 2023 in Phoenix, Arizona.
  • In addition, the Company presented safety, tolerability, pharmacokinetic, and pharmacodynamic data from RUBY-1, a phase 1 study of povetacicept in healthy adult volunteers.
  • In a model of murine experimental autoimmune myasthenia gravis (EAMG), povetacicept improved disease activity, with clinical scores superior to treatment with either the FcRn inhibitor efgartigimod or an anti-CD20 depleting antibody.
  • “These data indicate that povetacicept might deliver efficacy superior to some therapeutics currently in clinical use for myasthenia gravis and other autoantibody-related neurological diseases.

Amicus Therapeutics Announces Participation at the 2022 AANEM Annual Meeting

Retrieved on: 
Wednesday, September 21, 2022
Lists of diseases, Glycogen storage disease type II, Twitter, Amicus Therapeutics, PROPEL, Annual general meeting, LinkedIn, Poster, American Association, Therapy, Electrodiagnostic medicine, AANEM, Patient, Pompe, Association, GLOBE, Pharmaceutical industry

PHILADELPHIA, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced three poster presentations highlighting its development program for Pompe disease will be included at the 2022 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting , being held September 21-24, 2022 in Nashville, TN and virtually.

Key Points: 
  • PHILADELPHIA, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced three poster presentations highlighting its development program for Pompe disease will be included at the 2022 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting , being held September 21-24, 2022 in Nashville, TN and virtually.
  • For more information on the 2022 AANEM Annual Meeting, please visit www.aanem.org .
  • Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases.
  • With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases.

Clene Nanomedicine Presents Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific Conference

Retrieved on: 
Wednesday, September 21, 2022
Securities Exchange Act of 1934, Health, Safety, Multiple sclerosis, Lists of diseases, Twitter, Risk, Amyotrophic lateral sclerosis, MD, SALT, Survival, Securities Act of 1933, FAAN, Neurodegeneration, Remyelination, LinkedIn, Poster, Review, American Association, Electrodiagnostic medicine, Patient, AANEM, Quality of life, Annual report, Nasdaq, CNM, Neuroprotection, Episcopal conference, HR, CNS, ALS, Conference, Pharmacokinetics, Association, GLOBE, Marketing, R, Mortality, Neuron, OLE, Silviculture, Pharmaceutical industry, Facebook

Specifically, the poster evaluated the survival benefit associated with long-term CNM-Au8 treatment.

Key Points: 
  • Specifically, the poster evaluated the survival benefit associated with long-term CNM-Au8 treatment.
  • Sensitivity analyses of observed survival compared to predicted median survival derived from the published ENCALS prediction model based on each participants baseline study characteristics, with a data cutoff of August 31, 2022, also demonstrated a significant survival benefit with CNM-Au8 treatment (HR = 0.36, p=0.003).
  • CNM-Au8 treatment was well-tolerated, and there were no significant safety findings reported during the OLE.
  • Rob Etherington, Clenes CEO, added, The impressive ALS survival benefits seen with CNM-Au8 treatment corroborate our thesis energetic support of neurons may protect CNS health and slow neurodegenerative disease progression.

Health Union to Present Poster at American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting

Retrieved on: 
Tuesday, September 20, 2022
Myasthenia gravis, Annual general meeting, Health, American Association, Industry, Electrodiagnostic medicine, AANEM, Patient, Physician, Professional, Quality of life, Atrium Health Union, Research, Association, Management, Medical device, Medicine

PHILADELPHIA , Sept. 20, 2022 /PRNewswire/ -- Health Union, the leader in social health, has been accepted to present research about the impact that using myasthenia gravis-specific resources can have on medical care and various aspects of quality of life for people living with myasthenia gravis (MG) at the Annual Meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM). The research, in the form of a poster titled "Patient Perspectives Among Users of Myasthenia Gravis-Specific Community Resources – Can Community Resources Make An Impact?," will be presented from 8 a.m. to noon on Sept. 21 during the Myasthenia Gravis Foundation of America's Scientific Session.

Key Points: 
  • The research revealed that 77% of respondents used MG-specific community resources, including other MG patients and condition-specific websites and online support groups, to manage their MG.
  • The 2022 AANEM Annual Meeting offers physicians, technologists and other healthcare professionals the opportunity to learn about the latest in neuromuscular, musculoskeletal and electrodiagnostic medicine and advancements, including improving patient care, medical knowledge, interpersonal communication, professionalism, and systems-based practices.
  • Health Union is the proven industry leader driving and amplifying social health.
  • As the premier social health company, only Health Union encourages the dynamic, real-time action people take to find meaningful connections and share information that impact their health journey.

Pharnext: Findings on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A From ‘Real-World’ Digital Lifestyle Study, CMT&Me, to be Presented at the American Association of Neuromuscular & Electrodia

Retrieved on: 
Thursday, September 15, 2022
Therapy, II, ISIN, Prevalence, Convention center, Neurodegeneration, Poster, Life, Muscle atrophy, Medical Affairs Bureau, American Association of Neuromuscular & Electrodiagnostic Medicine, American Association, Electrodiagnostic medicine, AANEM, Charcot–Marie–Tooth disease, Patient, Wheelchair, PMP22, III, Schwann cell, Pain, Quality of life, CMT, Walking, Running, Degenerative disease, CET, Regulatory News Service, Conference, Association, Occupational therapy, Gaylord Opryland Resort & Convention Center, Pharmaceutical industry, Security (finance), Medical device, Television

Pharnext: Findings on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A From Real-World Digital Lifestyle Study, CMT&Me, to be Presented at the American Association of Neuromuscular & Electrodia

Key Points: 
  • Pharnext: Findings on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A From Real-World Digital Lifestyle Study, CMT&Me, to be Presented at the American Association of Neuromuscular & Electrodia
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The conference is taking place from September 21-24, 2022, in-person and with an option to participate virtually, at Gaylord Opryland Resort & Conference Center in Nashville, Tennessee.
  • Charcot-Marie-Tooth (CMT) disease encompasses a heterogeneous group of inherited, severe, debilitating, progressive and chronic peripheral neuropathies.
  • The genetic mutation responsible for CMT1A is a duplication of the PMP22 gene coding for a peripheral myelin protein.

argenx Reports Third Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Thursday, October 28, 2021
MSE, ITP, Annual general meeting, Yangon City Development Committee, Cancer, Disease, CIDP, Prescription Drug User Fee Act, Association, PDUFA, Chronic inflammatory demyelinating polyneuropathy, Organization, Partnership, Euronext, Patient, Pemphigus, Medison, Myositis, FDA, BLA, Food, GMG, DevOps, Review, Degenerative disease, MGFA, ADAPT, American Association, Food and Drug Administration, American Association of Neuromuscular & Electrodiagnostic Medicine, Protocol, AANEM, CMO, Myasthenia gravis, Electrodiagnostic medicine, Development, Consistency, Pharmaceutical industry

Breda, the Netherlands argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced its third quarter 2021 financial results and provided a business update and outlook for the remainder of the year.

Key Points: 
  • Breda, the Netherlands argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced its third quarter 2021 financial results and provided a business update and outlook for the remainder of the year.
  • This includes a first-in-class C2 inhibitor, ARGX-117, which is on track to begin the first Phase 2 trial in multifocal motor neuropathy patients by the end of this year.
  • Our growing commercial infrastructure along with our expanding pipeline ambitions provide considerable opportunity for argenx to deliver long-term, sustainable growth, concluded Mr. Van Hauwermeiren.
  • Additional data to be presented at upcoming Myasthenia Gravis Foundation of America (MGFA) Scientific Session.

argenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upcoming Neuromuscular Meetings

Retrieved on: 
Friday, October 8, 2021
Aurora, Treatment, Electrodiagnostic medicine, Degenerative disease, Myasthenia gravis, Euronext, Subgroup analysis, CIDP, AANEM, Comorbidity, MDT, MGFA, GMG, Quality of life, Cancer, United, ADAPT, Practice, American Association, Association, American Association of Neuromuscular & Electrodiagnostic Medicine, Efficacy, CO, Time, Conditional sentence, Review, Neurology, Annual general meeting, Pharmaceutical industry, Fireworks

The data will be presented at two upcoming neuromuscular meetings: the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting on October 13-16, 2021 in Aurora, CO and the virtual Myasthenia Gravis Foundation of America Scientific Session (MGFA) on October 30, 2021.

Key Points: 
  • The data will be presented at two upcoming neuromuscular meetings: the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting on October 13-16, 2021 in Aurora, CO and the virtual Myasthenia Gravis Foundation of America Scientific Session (MGFA) on October 30, 2021.
  • "The additional ADAPT data presented during these important neuromuscular forums strengthen our understanding of the value efgartigimod can offer as a potential treatment for people living with gMG.
  • Depth and consistency of disease score improvement, as well as a patient's ability to mount a vaccine response, are all key considerations for a treating physician," commented Wim Parys, M.D., Chief Medical Officer of argenx.
  • We will continue to listen to patients in uncovering the real-world burden associated with management of this debilitating, chronic disease."